Overview

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis

Status:
Completed

Trial end date:
2016-11-22

Target enrollment:

Participant gender:

Summary

This study evaluated the effects of an called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis. The purpose of this study was to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug). This study was able to test for efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen
Celgene Corporation

Treatments:

Apremilast
Thalidomide